MRI scans

AI tool has potential to better track MS lesions over time: Study

An artificial intelligence (AI) program, called iQ-MS, outperforms traditional radiologist-based measures at quantifying changes in lesions over time in people with multiple sclerosis (MS), a new study shows. “iQ-MS is a sensitive and accurate tool for monitoring MRI scans in people with MS by providing quantitative metrics that value-add…

Benefits of long-term Tysabri seen in RRMS patients in Japan: Study

Tysabri (natalizumab) significantly reduced the development of brain lesions on MRI scans in Japanese people with relapsing-remitting multiple sclerosis (RRMS), according to a new study. The therapy also eased or stabilized disability levels in most patients after five years of treatment, and significantly reduced the annual rate of…

MS Australia awards incubator grants to four research projects

Four researchers working in multiple sclerosis (MS) were awarded incubator grants in MS Australiaā€™s latest funding round, which theyā€™ll use to kickstart projects designed to better understand the progressive neurodegenerative disease. Worth a total of AU$92,565, or roughly $60,000, this round of incubator grants provides seed funding…

Icobrain MS, an AI tool for assessing MRI scans, being tested in UK

An upcoming study will investigate how well icobrain MS, anĀ artificial intelligence (AI)-based technology,Ā can interpret MRI dataĀ from people with multiple sclerosis (MS) and how its use might influence patient care. The project, called AssistMS and led by IcometrixĀ ā€” the technology’s developer ā€” and Queen Mary University of London…

Pixyl, Brainomix Partner on MRI Software to Help in Diagnosis of MS

In a new collaboration, Brainomix will distribute in Europe a software solution developed by Pixyl that uses deep learning to improve the diagnosis and monitoring of multiple sclerosis (MS) via MRI scans. According to the partners, Pixyl‘s technology can detect abnormalities on magnetic resonance imaging or MRI…

Researchers Distinguish Remyelinated Brain Lesions Via MRI

An MRI technique called quantitative susceptibility mapping (QSM) can be used to accurately identify remyelinated brain lesions in people with multiple sclerosis (MS), a research team has discovered. Remyelinated lesions are those in which the myelin sheath ā€” the protective coating around nerve fibers that is progressively lost…

Cambridge-1 ‘Supercomputer’ to Advance UK Research in Ills Like MS

Nvidia announced the launch of the U.K.ā€™s most powerful supercomputer ā€” calledĀ Cambridge-1 ā€” which uses a combination of artificial intelligence (AI) and simulation to help scientists to better understand complex diseases such as multiple sclerosis (MS) and to design new therapeutics. Cambridge-1 is the first supercomputer designed…

Need to Know: MS and Smoldering Lesions

Editor’s note: “Need to Knowā€ is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by two forum topics about silent inflammation from August 2019. Have an experience you want…

Treating MS Soon After Symptoms Appear Can Delay Relapses, Study Says

A long-term study underscoresĀ the potentialĀ benefits, especially in terms of relapses,Ā ofĀ multiple sclerosis (MS) patients beginning treatment as soon as possible after symptomsĀ appear ā€” even before the disease is definitely diagnosed.Ā ā€œThe 11-year long-term follow-up study from the randomized BENEFIT CIS trialā€ was published in the journal Neurology. Researchers in…

For MS Patients, New Guidelines for Controlling Rare Brain Infection Risk Under Tysabri Treatment

The European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC), responsible for assessing and monitoring safety issues for human medicines, completedĀ a review on the risk for progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with the medicine Tysabri (natalizumab). The issued guidelines have the objective of minimizing patientsā€™ risk.

Guidelines Issued for Monitoring of MS Patients on Natalizumab Treatment

A panel of neurologists from the U.K. and Ireland recently developed practical consensus guidelines for monitoring multiple sclerosis (MS) patients on natalizumab (Tysabri)Ā therapy for the risk of developing progressive multifocal leukoencephalopathy (PML), a life-threatening viral infection caused by the John Cunningham (JC) virus. The panel was summoned by…